FOXO1 and metabolic dysfunction-associated steatotic liver disease: On the one hand, hepatic FOXO1 overexpression promoted triglycerides (TG) accumulation, decreased fatty acid oxidation (FAO), and exacerbated MASLD progression in mice [56].